HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mooradian, A. D. Articles by Wong, N. C.W. Search for Related Content PubMed PubMed Citation Articles by Mooradian, A. D. Articles by Wong, N. C.W.

---

ORIGINAL ARTICLE

Apolipoprotein A-I Expression in Rats Is Not Altered by Troglitazone¹

Arshag D. Mooradian^*,2, Michael J. Haas^*, Joe Chehade^* and Norman C.W. Wong

^* The Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, St. Louis University Medical School, St. Louis, MO 63104; and
the Division of Endocrinology, University of Calgary, Calgary, Alberta, Canada T2N4N1

Insulin is known to upregulate apolipoprotein A-I (apoA-I) promoter activity and to increase apoA1 gene expression in vivo. To determine if enhancement of insulin action with insulin sensitizers can also increase the apoA-I expression, we studied the in vivo effect of troglitazone, a potent insulin sensitizer, on the expression of rat hepatic and intestinal apoA-I mRNA using Northern blot analysis. The plasma, hepatic, and intestinal apoA-I content was also measured with immunoblot analysis using a specific anti-rat apoA-I antiserum. Troglitazone, given mixed with rat chow (0.2%) for 18 days, did not increase either plasma or tissue apoA-I mRNA or protein content. Intestinal apoA-I mRNA content relative to glyceraldehyde-3 phosphate dehydrogenase (G₃PDH) mRNA was significantly lower compared with hepatic tissue content in both control and troglitazone-treated rats. The effect of troglitazone on the rat apoA-I promoter was examined using transient transfection analysis in HepG2 cells transfected with the apoA-I-chloramphenicol acetyl transferase (CAT) reporter plasmid (pAI.474.CAT). CAT activity (percentage acetylation of chloramphenicol as means ± SEM) was not significantly different in ethanol (vehicle)-treated cells compared with cells treated with troglitazone (50.5% ± 2.5% in control cells vs 57.7% ± 8.2% and 53.5% ± 4.2% in cells treated with 10 and 100 mM troglitazone, respectively). It is concluded that troglitazone doses known to achieve insulin sensitization did not enhance rat apoA-I promoter activity sufficiently to result in an increased apoA-I mRNA or protein expression in the intact rat. However, peroxisome proliferator activator receptor (PPAR) agonists that have significant PPAR activity in addition to their PPAR effects, may well be able to induce apoA-I expression.

Key Words: atherosclerosis • thiazolidinediones • high density lipoprotein • apolipoprotein A-I

This article has been cited by other articles:

				S. Qin, T. Liu, V. S. Kamanna, and M. L. Kashyap Pioglitazone Stimulates Apolipoprotein A-I Production Without Affecting HDL Removal in HepG2 Cells: Involvement of PPAR-{alpha} Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2428 - 2434. [Abstract] [Full Text] [PDF]

				A. D. Mooradian, M. J. Haas, and N. C. W. Wong The Effect of Select Nutrients on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I Levels Endocr. Rev., February 1, 2006; 27(1): 2 - 16. [Abstract] [Full Text] [PDF]

				A. D. Mooradian, M. J. Haas, and N. C.W. Wong Transcriptional Control of Apolipoprotein A-I Gene Expression in Diabetes Diabetes, March 1, 2004; 53(3): 513 - 520. [Abstract] [Full Text] [PDF]